Clinical Trial Update: Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab in combination with rituximab or obinutuzumab for relapsed or refractory follicular lymphoma or diffuse large B-cell ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Gazyva (Obinutuzumab)
• KEYTRUDA (PEMBROLIZUMAB)
• Rituxan (rituximab)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2025-04-18